CLINICAL_TRIALS
trial_result
· 2016-10-17
Clinical Trial Update: RDEA119 and Sorafenib Combination Dose Escalation Study [Phase 1, Phase 2]
Summary
A completed phase 1/2 dose-escalation study evaluating the combination of RDEA119 with sorafenib in patients with advanced cancer.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Bayer | Conditions: Advanced Cancer | Phase 1, Phase 2 | Status: COMPLETED